200 related articles for article (PubMed ID: 32249812)
21. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup.
Liu YJ; Houldsworth J; Emmadi R; Dyer L; Wolff DJ
Cancer Genet; 2020 Jun; 244():40-54. PubMed ID: 32434132
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA profiling of human kidney cancer subtypes.
Petillo D; Kort EJ; Anema J; Furge KA; Yang XJ; Teh BT
Int J Oncol; 2009 Jul; 35(1):109-14. PubMed ID: 19513557
[TBL] [Abstract][Full Text] [Related]
23. Chromophobe renal cell carcinoma: New genetic and metabolic insights.
Zhang L; Henske EP
Urol Oncol; 2020 Aug; 38(8):678-681. PubMed ID: 32444178
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetics of renal carcinogenesis.
Walker C
Toxicol Pathol; 1998; 26(1):113-20. PubMed ID: 9502393
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
26. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
Tickoo SK; dePeralta-Venturina MN; Harik LR; Worcester HD; Salama ME; Young AN; Moch H; Amin MB
Am J Surg Pathol; 2006 Feb; 30(2):141-53. PubMed ID: 16434887
[TBL] [Abstract][Full Text] [Related]
28. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities.
Hoerner CR; Miao SY; Hsieh JJ; Fan AC
Cancer J; 2020; 26(5):407-418. PubMed ID: 32947309
[TBL] [Abstract][Full Text] [Related]
29. Sequential reinforcement active feature learning for gene signature identification in renal cell carcinoma.
Huang M; Ye X; Imakura A; Sakurai T
J Biomed Inform; 2022 Apr; 128():104049. PubMed ID: 35283266
[TBL] [Abstract][Full Text] [Related]
30. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
[TBL] [Abstract][Full Text] [Related]
31. [Expression of Ksp-cadherin in renal epithelial neoplasm and its clinicopathologic significance].
Rao Q; Zhou XJ; Shi QL; Yin HL; Ma HH; Zhou HB; Zhang RS
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):15-8. PubMed ID: 17374232
[TBL] [Abstract][Full Text] [Related]
32. Network spatio-temporal analysis predicts disease stage-related genes and pathways in renal cell carcinoma.
Li1 XH; Yang CZ; Wang J
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173324
[TBL] [Abstract][Full Text] [Related]
33. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
[TBL] [Abstract][Full Text] [Related]
34. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
35. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
36. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization.
Junker K; Weirich G; Amin MB; Moravek P; Hindermann W; Schubert J
Recent Results Cancer Res; 2003; 162():169-75. PubMed ID: 12790331
[TBL] [Abstract][Full Text] [Related]
37. Ectopic expression of the TERE1 (UBIAD1) protein inhibits growth of renal clear cell carcinoma cells: altered metabolic phenotype associated with reactive oxygen species, nitric oxide and SXR target genes involved in cholesterol and lipid metabolism.
Fredericks WJ; Yin H; Lal P; Puthiyaveettil R; Malkowicz SB; Fredericks NJ; Tomaszewski J; Rauscher FJ; Malkowicz SB
Int J Oncol; 2013 Aug; 43(2):638-52. PubMed ID: 23759948
[TBL] [Abstract][Full Text] [Related]
38. BSND and ATP6V1G3: Novel Immunohistochemical Markers for Chromophobe Renal Cell Carcinoma.
Shinmura K; Igarashi H; Kato H; Koda K; Ogawa H; Takahashi S; Otsuki Y; Yoneda T; Kawanishi Y; Funai K; Takayama T; Ozono S; Sugimura H
Medicine (Baltimore); 2015 Jun; 94(24):e989. PubMed ID: 26091477
[TBL] [Abstract][Full Text] [Related]
39. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
Weiss RH
Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
Kauffman EC; Barocas DA; Chen YT; Yang XJ; Scherr DS; Tu JJ
J Urol; 2009 May; 181(5):2305-11. PubMed ID: 19303095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
